This Fund Bought $38 Million of Celcuity as Stock Surges on Investigational Cancer Drug Results

Apis Capital Advisors disclosed a new 13F position in Celcuity, acquiring 776,000 shares valued at $38.33 million as of Sept. 30, representing 8.5% of the fund's $452.7 million reportable U.S. equity assets. Celcuity shares trade at $100.35 (market cap ~$4.6 billion), with trailing twelve‑month revenue of $0 and a net loss of $162.7 million, while the company has advanced gedatolisib with positive Phase 3 results and filed an NDA on Nov. 17. The sizeable stake by an institutional manager and the recent regulatory filing together underpin investor conviction and create a potential regulatory/commercial inflection point that could re-rate the stock if FDA approval and commercialization milestones are achieved.

Analysis

Market structure: Apis’ 776k-share, $38.3M stake in CELC concentrates institutional ownership and validates momentum-driven demand for precision-oncology stories. Direct winners: Celcuity (equity holders), diagnostic partners and momentum funds; losers: non-targeted chemo incumbents and small-cap biotech peers that lose flow. The 669% YTD move implies a tight supply/float dynamic — modest sell-side liquidity will amplify moves and keep options IV elevated, while macro fixed‑income/FX impacts are negligible except idiosyncratic stress on high‑yield biotech credit.

Risk assessment: The thesis is binary — FDA/NDA outcome and real‑world diagnostic uptake are high‑impact tail risks (regulatory denial, safety surprises, or inability to secure reimbursement could halve+ market cap quickly). Immediate (days) risk = headline-driven volatility; short-term (weeks–months) = NDA review (expect decision ~6–10 months post‑NDA) and potential secondary offering if cash runway <12 months; long-term (12–36 months) = commercialization, label breadth, and payer acceptance. Hidden dependencies include companion-diagnostic validation, partner licensing, and dilution timing.

Trade implications: For tactical exposure favor defined-risk structures: small core long (1–1.5% NAV) hedged with 12‑month 30% OTM puts or a 6–9 month call spread (buy Jul‑2026 $90C / sell Jul‑2026 $180C) sized 0.5–1% NAV. Pair trade: long CELC / short IBB (equal notional, 0.5%) to isolate stock-specific binary risk. Rotate modestly from undifferentiated small‑cap biotech into precision‑oncology/diagnostics (e.g., GH) over 3 months.

Contrarian angles: Consensus is underweight dilution and commercialization execution risk — $4.6B market cap with $0 revenue and ongoing losses is speculative until payer economics are proven. Historical parallels (single‑asset runups later collapsed after regulatory/commercial setbacks) argue keeping unhedged exposure <2% NAV and treating any sustained >150% market‑cap expansion pre‑revenue as froth. Concentrated institutional ownership also raises liquidity and squeeze risk on downside events.

Key Decisions for Investors

• Establish a tactical long position in CELC equal to 1.0–1.5% of portfolio NAV, scale in over 6–12 weeks on pullbacks up to 20–30%, and limit unhedged exposure to <2% NAV.
• Buy a defined‑risk bullish call spread sized 0.5–1.0% NAV: Jul‑2026 CELC $90C / Jul‑2026 $180C to participate in upside ahead of FDA decision while capping premium cost.
• For downside protection on positions >1% NAV, purchase 12‑month CELC puts ~30% OTM (or implement collars) and reduce exposure if Celcuity’s latest 10‑Q shows cash runway <12 months or management announces a secondary offering.
• Implement a relative value pair: go long CELC and short IBB notional‑matched at 0.5% NAV to isolate idiosyncratic binary risk; trim long CELC by 50% on FDA approval or if CELC shares appreciate +100% from entry, cut losses at −35% unhedged.